Intravenous Cardiac Stem Cell-Derived Exosomes Ameliorate Cardiac Dysfunction in Doxorubicin Induced Dilated
Adam C Vandergriff1, James Bizetto Meira de Andrade2, Junnan Tang3
1Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27695, USA ; Joint Department of Biomedical Engineering, UNC-Chapel Hill and NC State University, Chapel Hill and Raleigh, NC, USA.
Insights
Cardiac stem cell-derived exosomes (CSC-XOs) offer a promising alternative to stem cell therapy for cardiomyopathies. Systemic delivery of human CSC-XOs improved heart function and reduced damage in mice without adverse immune reactions.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Exosome Biology
Background:
- Cardiac stem cells (CSCs) show therapeutic potential for cardiomyopathies but face limitations.
- CSC-derived exosomes (CSC-XOs) mediate many of the regenerative effects attributed to CSCs.
- Exosomes offer a cell-free therapeutic approach to overcome stem cell limitations.
Purpose of the Study:
- To investigate the therapeutic potential of systemically delivered human CSC-XOs in a mouse model of dilated cardiomyopathy.
- To evaluate the effects of CSC-XOs on cardiac function, apoptosis, and fibrosis.
- To assess the immunogenicity of human CSC-XOs in immunocompetent mice.
Main Methods:
- A mouse model of doxorubicin-induced dilated cardiomyopathy was established.
- Human CSC-XOs were administered systemically to the mice.
- Echocardiography was used to assess cardiac function.
- Histological analysis was performed to evaluate apoptosis and fibrosis.
Main Results:
- Systemic delivery of CSC-XOs significantly improved cardiac function in mice.
- CSC-XO treatment led to decreased apoptosis and fibrosis in the heart.
- No adverse immune reactions were observed despite using human CSC-XOs in immunocompetent mice.
Conclusions:
- Human CSC-XOs demonstrate significant therapeutic efficacy in a preclinical model of dilated cardiomyopathy.
- CSC-XOs represent a promising cell-free therapeutic strategy for cardiac repair.
- The lack of immunogenicity suggests CSC-XOs could be a viable alternative to CSC transplantation.
Abstract:
Despite the efficacy of cardiac stem cells (CSCs) for treatment of cardiomyopathies, there are many limitations to stem cell therapies. CSC-derived exosomes (CSC-XOs) have been shown to be responsible for a large portion of the regenerative effects of CSCs. Using a mouse model of doxorubicin induced dilated cardiomyopathy, we study the effects of systemic delivery of human CSC-XOs in mice. Mice receiving CSC-XOs showed improved heart function via echocardiography, as well as decreased apoptosis and fibrosis. In spite of using immunocompetent mice and human CSC-XOs, mice showed no adverse immune reaction. The use of CSC-XOs holds promise for overcoming the limitations of stem cells and improving cardiac therapies.
